Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cardiomyopathy
Pharma
JPM25: BridgeBio's cardiomyopathy drug is off to a roaring start
Less than two months after scoring an FDA nod, BridgeBio's cardiomyopathy drug Attruby is already muscling in on Vyndaqel's turf.
Fraiser Kansteiner
Jan 13, 2025 9:40pm
Look out, Pfizer: BridgeBio gains 'best-case' FDA nod for Attruby
Nov 25, 2024 7:59am
Alnylam sees Amvuttra as potential standard of care in ATTR-CM
Aug 30, 2024 10:06am
Pfizer, Alnylam and BMS: US poised for huge CV disease jump
Jul 8, 2022 11:00am
Bristol's heart med mavacamten passed muster at the FDA
Apr 29, 2022 3:33am
